 Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ), co-invested by Hong Kong CITIC Pacific Ltd. and Shanghai Lansheng Group, is a biopharmaceutical company with leading high technology. Established in Jan. 1998, it is located in Zhangjiang Hi-tech Park, Pudong New Area, Shanghai with a floor area of 58,080 sqm and construction area of 56,000 sqm. The total registered capital of the company is 686 million RMB yuan and total investment is amounted to over 1 billion RMB yuan.
CPGJ engages in R&D and industrialization of humanized monoclonal antibody drugs which are categorized as the 3rd generation of bio-tech products with reputation of “Biomissiles”. With high specificity, documented efficacy, less side-effects and better safety profile, these products are becoming more and more widely used in the treatment of serious diseases detrimental to human health. With 8-year experience, CPGJ has possessed the core technology of antibody screening, antibody structure remodeling, high-expressing cell line generation and large-scale production. CPGJ has also several advanced platforms for pilot scale-up technology. With international leading technology and persistent innovation ability, CPGJ is scheduling to launch over 10 humanized therapeutic antibodies on the market or clinical trials.
CPGJ has committed to develop and industrialize humanized monoclonal antibody drugs, aiming to contribute for the Chinese Biotechnology’s advancement and human healthcare improvement. CPGJ believes: Seek harmony, value honesty and keep the nation healthy.
|
